Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (AIM) is a clinical-stage biopharmaceutical company pioneering RNA-based therapeutics for cancer, viral diseases, and immune disorders. This dedicated news hub provides investors and researchers with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access verified information about Ampligen clinical progress, Alferon N Injection research, and collaborative studies with global institutions. Our curated news collection covers FDA communications, trial phase results, intellectual property updates, and scientific conference presentations.
Key updates include oncology treatment advancements, antiviral therapy research, and partnership announcements with organizations like Japan's National Institute of Infectious Diseases. Bookmark this page for real-time access to AIM's latest developments in immuno-pharmaceutical innovation.
AIM ImmunoTech Inc. has completed cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), a dsRNA product candidate for cancer, viral diseases, and immune disorders. CEO Thomas K. Equels emphasized the importance of this milestone for the company's development and commercial strategies, highlighting ongoing clinical trials for solid tumors.
AIM ImmunoTech Inc. announced positive results in testing Ampligen and Imfinzi in late-stage pancreatic cancer treatment. The combination was well-tolerated with no severe adverse events. The next safety cohort will start escalated dosing soon. Subjects will be monitored for response for up to 48 weeks.